Neuroscience Trials Australia

What Neuroscience Trials Australia does

Neuroscience Trials Australia (NTA) is a Melbourne-based not-for-profit Contract Research Organisation established in 2001 and a wholly-owned subsidiary of The Florey Institute of Neuroscience and Mental Health, the largest brain research institute in the southern hemisphere. It provides full-service clinical trial management across Phase I-IV for pharmaceutical, biotechnology, cell therapy, and medical device companies, as well as investigator-initiated studies. Core services span protocol and CRF design, study feasibility and start-up, project management, site monitoring (including risk-based monitoring), safety and pharmacovigilance, quality assurance, data management, biostatistics, and medical writing, delivered under a GxP-compliant Quality Management System with submissions to the TGA, FDA and EMA. Its core therapeutic specialization is central nervous system (CNS) and neuroscience — including Alzheimer's, Parkinson's, stroke, mental health, Huntington's, multiple sclerosis, neuromuscular disease, brain and spinal cord injury, and psychedelics — with secondary exposure to oncology tracers, immunology, ophthalmology, endocrinology, COVID-19, rare paediatric disease, genetic disorders, sleep disorders, devices and diagnostics.

NTA's business model is project-based professional services, pricing per trial scope, phase, and therapeutic area. Commercial channels are primarily direct B2B enterprise engagement supported by referrals through The Florey Institute's clinical and scientific network. The company's value proposition packages Australia's regulatory and fiscal advantages — TGA's no-IND pathway enabling site start-up in 5-6 weeks and saving up to 12 months of regulatory time, and the Australian Government R&D Tax Incentive returning up to 43.5 cents per dollar of R&D spend. Customers cited include Cortexyme, ES Therapeutics, Immune Bio, Dementia Trials Australia, Royal Melbourne Hospital, and Griffith University. As a not-for-profit, NTA reinvests surplus into neuroscience research at The Florey, and the brand is currently transitioning from 'Neuroscience Trials Australia' to 'Florey Trials' under ongoing website redevelopment.

Name

Neuroscience Trials Australia

Legal name

Neuroscience Trials Australia

Website

https://neurosciencetrialsaustralia.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

Neuroscience Trials Australia is a not-for-profit, full-service clinical research organisation (CRO) specialising in Phase I-IV neuroscience and CNS clinical trials for pharmaceutical, biotech, cell therapy and device clients, operating from Melbourne as a subsidiary of the Florey Institute.

Ownership category

akta.pro rank

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Clinical trial management
• Neuroscience research services
• Contract research organization
• CNS clinical trials
• Pharmaceutical research services

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

Revenue model

1. Clinical Research Services: NTA generates revenue through providing full-service clinical trial management for pharmaceutical, biotechnology, cell therapy and device companies. Services span Phase I-IV clinical trials including protocol design, study start-up, monitoring, data management, biostatistics, medical writing and quality assurance.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Neuroscience Trials Australia is a niche Australian-owned full-service Clinical Research Organisation (CRO) specialising in neuroscience and CNS clinical research. It provides end-to-end Phase I-IV clinical trial management services including protocol and CRF design, study feasibility, start-up, project management, site monitoring, risk-based monitoring, safety and pharmacovigilance, data management, biostatistics, medical writing, and quality assurance. Services are delivered to pharmaceutical, biotechnology, cell therapy, and device companies across therapeutic areas spanning Alzheimer's, Parkinson's, stroke, mental health, psychedelics, and other indications.

Product overview

Neuroscience Trials Australia operates as a niche Australian-owned full-service Contract Research Organization (CRO) specializing in neuroscience clinical research with over 20 years of experience. The company's core offering is its comprehensive Clinical Trial Management Services covering Phase I-IV clinical development, including protocol and CRF design, study feasibility, start-up, project management, site monitoring, risk-based monitoring, safety and pharmacovigilence, quality assurance, data management, biostatistics, and medical writing. NTA's therapeutic expertise spans neuroscience conditions (Alzheimer's disease, stroke, mental health, Parkinson's disease, brain and spinal cord injury, Huntington's disease, neuromuscular disease, psychedelics) and other therapeutic areas (rare paediatric disease, genetic disorders, sleep disorders, oncology tracers, immunology, ophthalmology, endocrinology, allergy, COVID-19, devices, diagnostics). The company leverages its unique network as a subsidiary of The Florey Institute of Neuroscience and Mental Health to provide direct access to therapeutic disease specialists, key opinion leaders, and clinical trial sites.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Study site start-up achievable within 5-6 weeks
• +2 more outcomes

Named customers7 records

Segments4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• The Florey Institute of Neuroscience and Mental HealthcoreStrategic or Co-development PartnerNTA is a subsidiary of The Florey Institute of Neuroscience and Mental Health, the largest brain research institute in the southern hemisphere. This affiliation provides NTA with direct access to therapeutic disease specialists, key opinion leaders, and clinical trial sites. The relationship enables NTA to deliver quality clinical trial services with strong recruitment outcomes through this unique professional network. NTA is located in the health and academic precinct next to Melbourne CBD.
• Australia and New Zealand Movement Disorders Clinical Research Network (ANZ-MD-CRN)supportingStrategic or Co-development PartnerNTA provides administrative support to the network and endeavors to seek out new clinical trials in Parkinson's disease and other movement disorders relevant to the network's expertise.
• Dementia Trials AustraliasupportingStrategic or Co-development PartnerNTA is Australia's foremost not-for-profit CRO specializing in research support for Dementia Trials Australia. NTA helps attract clinical trials to Australia and provides invaluable support to clinical trial sites. NTA also supports the Dementia Trials Australia Annual Scientific Meeting.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Regional players

• CMAX Clinical Research: CMAX Clinical Research is an Australian-based early-phase clinical trial unit based in Adelaide specializing in first-in-human and Phase I/II studies for biotech and pharma sponsors. It is a regional peer given shared Australian early-phase focus and similar biotech client base.
• Avance Clinical: Avance Clinical is an Australian-owned CRO specializing in early-phase clinical trials for biotech sponsors, leveraging the same R&D tax incentive and TGA regulatory advantages NTA promotes. It is a regional peer given overlapping Australian geographic focus and similar biotech early-phase client base.
• Novotech: Novotech is a leading Asia-Pacific focused CRO providing full-service clinical trial management to biotech sponsors, with significant operations in Australia. It is a regional peer given shared Australian operational footprint and similar biotech-targeted CRO business model.
• Linear Clinical Research: Linear Clinical Research is an Australian early-phase clinical trial facility based in Perth, conducting Phase I trials for biotech and pharma sponsors. It is a regional peer given shared Australian early-phase focus and overlap in CNS and adjacent therapeutic areas.
• Clinical Network Services (CNS): Clinical Network Services is an Australian-based CRO providing biopharmaceutical development services including clinical trial management and regulatory affairs. It is a regional peer given shared Australian location and similar full-service CRO model targeting biotech sponsors.

Broad incumbents

• Parexel: Parexel is a global CRO with established neuroscience and rare disease clinical development capabilities serving pharma and biotech sponsors. It is a broad incumbent peer given overlapping CNS expertise and full-service delivery, though it operates globally with broader therapeutic area coverage.
• ICON plc: ICON plc is a global CRO providing outsourced clinical development and consulting services across all major therapeutic areas including CNS. It is a broad incumbent peer given overlapping full-service Phase I-IV delivery model, though operating at much larger global scale than NTA.
• Syneos Health: Syneos Health is a global clinical and commercial services organization providing Phase I-IV CRO services across therapeutic areas including neuroscience. It is a broad incumbent peer given overlapping CRO service offerings and biopharma client base.
• IQVIA: IQVIA is the largest global CRO and life sciences services company offering full Phase I-IV clinical development across all therapeutic areas including neuroscience. It is a broad incumbent peer given overlapping CNS trial capabilities, but at vastly larger scale and broader portfolio than NTA's specialist focus.

Direct peers

• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO with a dedicated neuroscience/CNS practice spanning early- through late-phase trials. It is a direct peer to NTA given its specialty focus on CNS indications and similar full-service delivery model for biopharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/neurotrialsaus
• LinkedInlinkedin.com/company/neurosciencetrialsaustralia

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuroscience Trials Australia